Ono Pharmaceutical

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, DPSI, UNIT

Retrieved on: 
Saturday, May 4, 2024
Sale, Advertising, UMB Financial Corporation, Ono Pharmaceutical, UNIT, UMB, Elliott Investment Management, Windstream Holdings, Fraud, Security (finance)

If you are a Deciphera shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Deciphera shareholder, click here to learn more about your rights and options .
  • DecisionPoint Systems, Inc. (NYSE: DPSI)’s sale to an affiliate of Barcoding Holdings, LLC for $10.22 in cash per share.
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH

Retrieved on: 
Wednesday, May 1, 2024
Class Action Lawsuit, Professional Services, Legal, Sale, KSF, Ono Pharmaceutical

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS: DCPH) to ONO Pharmaceutical Co., Ltd.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS: DCPH) to ONO Pharmaceutical Co., Ltd.
  • Under the terms of the proposed transaction, shareholders of Deciphera will receive $25.60 in cash for each share of Deciphera that they own.
  • Please note that the transaction is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, April 29, 2024
Class Action Lawsuit, Professional Services, Legal, Sale, ONO, Ono Pharmaceutical, Advertising, Fraud

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to ONO Pharmaceutical Co., Ltd. for $25.60 per share in cash is fair to Deciphera shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to ONO Pharmaceutical Co., Ltd. for $25.60 per share in cash is fair to Deciphera shareholders.
  • On behalf of Deciphera shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

Retrieved on: 
Monday, April 29, 2024
Biotechnology, Pharmaceutical, Health, Oncology, USD, Patient, Cancer, Acquisition, Research, Growth, GIST, Tenosynovial giant cell tumor, ONO, ULK, TGCT, Ono Pharmaceutical, Disease, BofA Securities, Drug discovery, Pharmaceutical industry

Together, ONO and Deciphera will accelerate their shared vision to deliver innovative new drugs and serve patients around the world.

Key Points: 
  • Together, ONO and Deciphera will accelerate their shared vision to deliver innovative new drugs and serve patients around the world.
  • If the tender offer conditions are not satisfied, ONO may be required to extend the tender offer under certain circumstances.
  • Upon completion of the Acquisition, Deciphera will operate as a standalone business of ONO Group, from its headquarters in Waltham, Massachusetts.
  • J.P. Morgan Securities LLC is serving as exclusive financial advisor to Deciphera and Goodwin Procter LLP is serving as legal counsel.

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Retrieved on: 
Monday, April 8, 2024
Research, SOC, Conference, CPI, Ono Pharmaceutical, Patient, Standard of care, Inflammation, Pembrolizumab, IND, Investigational New Drug, WT1, Nivolumab, SITC, FDA, Autoimmunity, Annual general meeting, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.

Key Points: 
  • BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.
  • The increase was due to revenue earned from our strategic collaboration agreement entered into with Ono Pharmaceutical in the first quarter of 2023.
  • As of December 31, 2023, the Company had approximately $48.5 million in cash, cash equivalents and marketable securities compared with $76.3 million as of December 31, 2022.
  • We expect our current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2025.

Cue Biopharma to Host Business Update Call and Webcast

Retrieved on: 
Tuesday, April 2, 2024
EDT, Ono Pharmaceutical

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT.

Key Points: 
  • BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT.
  • Live and archived versions of the event can be accessed via the Company’s website .
  • The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional autoimmune pipeline developments and business updates.
  • Monday, April 8 at 4:30 p.m. EDT

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Retrieved on: 
Monday, April 1, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, EOS, Itolizumab, Week, S1P, Dialysis, Type, AMP, Exercise, Ono Pharmaceutical, Infection, Lymphocytopenia, Patient, Serum albumin, Peripheral edema, CD6, Lupus, EULAR, EGFR, Therapy, Proteinuria, ALC, Lupus nephritis, Nursing

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients.

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from the Type B portion of the Phase 1b EQUALISE study evaluating itolizumab in lupus nephritis patients.
  • Key topline data from the Type B portion of the EQUALISE study in lupus nephritis:
    Subjects were highly proteinuric: baseline mean UPCR of 4.9 g/g.
  • Itolizumab treatment (over 6 months) was also associated with reductions in absolute lymphocyte counts (ALC), another known pharmacodynamic effect.
  • Two subjects had at least one serious adverse event, none of which were related to study treatment.

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Retrieved on: 
Friday, March 22, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Therapy, Conference, Ono Pharmaceutical

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, and the LD Micro Invitational Conference.
  • Management will provide an overview of the company’s clinical programs, partnership with Ono Pharmaceutical and 2024 milestones, during both conferences.
  • Webcast access will be available on the “Events & Presentations” page under the Investor Relations tab on the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.... .
  • The presentation at the LD Micro conference will be live-streamed on the event website at https://ldinv14.sequireevents.com/ .

Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders

Retrieved on: 
Thursday, March 14, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Discovery, Central nervous system, Entrepreneurship, Ono Pharmaceutical, Partnership, Patient, CNS, Doctor of Philosophy, Protein, Senior, Protein folding, Drug development, Pharmaceutical industry

Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System (CNS) disorders.

Key Points: 
  • Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System (CNS) disorders.
  • Ono Pharmaceutical plans to harness this technology to address some of the most challenging aspects of CNS drug development by targeting proteins involved in complex neurological pathways.
  • Together, we aim to unlock new therapeutic possibilities for patients worldwide,” commented Lidia Pieri, PhD, Co-Founder and Chief Executive Officer of Sibylla Biotech.
  • “I am honored to collaborate with the Ono Pharmaceutical team, whose rich history, expertise and culture I greatly appreciate, and all of us at Sibylla look forward to working closely with them.”

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Retrieved on: 
Monday, March 11, 2024
Ignis, Civil service commission, Epilepsy, ASM, Ono Pharmaceutical, Partnership, Central nervous system, Patient, CNS, News, MHRA, Cenobamate, MENA, European Commission, Greater China, FDA, Swissmedic, Food, Pharmaceutical industry

GYEONGGI, Korea, and ROME, March 11, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, and the first and only Korean company to independently develop and commercialize a new drug in the U.S., today announced more than 100,000 patients have been treated globally with cenobamate, an anti-seizure medication (ASM) developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc.

Key Points: 
  • In the U.S., cenobamate is marketed under the brand name XCOPRI® (cenobamate tablets) CV.
  • Since 2023, Dexcel Pharma, an international specialty pharmaceutical company, has been marketing cenobamate in Israel, and Paladin Labs Inc., launched cenobamate in Canada.
  • "This cenobamate milestone coincides with the completion earlier this year of SK Biopharmaceuticals' strategic Global Partnering plan.
  • "We are excited to continue transforming the landscape of epilepsy care with innovative treatment options and to advocate for epilepsy as a priority for healthcare systems across Europe."